OneSource Specialty Pharma Limited (IN:ONESOURCE)
:ONESOURCE
Want to see IN:ONESOURCE full AI Analyst Report?
ONESOURCE Stock Chart & Stats
₹1540.35
--
Market closed
₹1540.35
--
Day’s Range― - ―
52-Week Range₹1,075.00 - ₹2,249.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.94K
Market Cap
₹214.11B
Enterprise Value₹227.51B
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹12.95B
Price to Earnings (P/E)920.2
Beta0.50
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,642,654
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.15
Revenue Forecast (FY)₹22.08B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~77% revenue surge in FY2026 represents durable top-line expansion and stronger commercial traction. Sustained revenue growth provides a larger base for operating leverage, supports reinvestment in R&D and commercialization, and creates scope to improve margins over the next several quarters.
Top-line Momentum After Flat YearRecovering from a flat year to strong acceleration indicates successful execution on product launches or market penetration. This discrete step-up suggests improving demand or distribution; if sustained, it can underpin multi-quarter growth and justify ongoing operational scale-up investments.
Balance Sheet CushionA relatively large equity base versus debt historically provides financial flexibility to fund operations or absorb losses without immediate solvency stress. This cushion helps the company bridge reinvestment or restructuring while pursuing sustainable margin recovery over the medium term.
Bears Say
Cash Generation WeaknessPersistent negative operating and free cash flow is a structural concern: the business is burning cash to operate and invest. Over the next 2-6 months this limits the company’s ability to self-fund growth, raises refinancing or dilution risk, and constrains discretionary spending like marketing or R&D.
Profitability DeteriorationA material swing into loss and sharply weaker EBIT signals margin compression and cost escalation relative to revenue. Sustained losses undermine return on invested capital, force cost retrenchment or additional funding, and make it harder to translate revenue growth into durable shareholder value.
Rising Debt Amid LossesIncreasing debt while earnings decline raises solvency and interest-service risk. If losses persist, higher leverage narrows strategic options, increases financing costs, and may force asset sales or equity raises, making medium-term recovery more capital-intensive and potentially dilutive.
OneSource Specialty Pharma Limited News
ONESOURCE FAQ
What was OneSource Specialty Pharma Limited’s price range in the past 12 months?
OneSource Specialty Pharma Limited lowest stock price was ₹1075.00 and its highest was ₹2249.65 in the past 12 months.
What is OneSource Specialty Pharma Limited’s market cap?
OneSource Specialty Pharma Limited’s market cap is ₹214.11B.
When is OneSource Specialty Pharma Limited’s upcoming earnings report date?
OneSource Specialty Pharma Limited’s upcoming earnings report date is Aug 10, 2026 which is in 80 days.
How were OneSource Specialty Pharma Limited’s earnings last quarter?
OneSource Specialty Pharma Limited released its earnings results on May 13, 2026. The company reported ₹0.4 earnings per share for the quarter, the consensus estimate of ₹0.4 by ₹0.
Is OneSource Specialty Pharma Limited overvalued?
According to Wall Street analysts OneSource Specialty Pharma Limited’s price is currently Overvalued.
Does OneSource Specialty Pharma Limited pay dividends?
OneSource Specialty Pharma Limited does not currently pay dividends.
What is OneSource Specialty Pharma Limited’s EPS estimate?
OneSource Specialty Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OneSource Specialty Pharma Limited have?
OneSource Specialty Pharma Limited has 114,642,654 shares outstanding.
What happened to OneSource Specialty Pharma Limited’s price movement after its last earnings report?
OneSource Specialty Pharma Limited reported an EPS of ₹0.4 in its last earnings report, expectations of ₹0.4. Following the earnings report the stock price went down -2.34%.
Which hedge fund is a major shareholder of OneSource Specialty Pharma Limited?
Currently, no hedge funds are holding shares in IN:ONESOURCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
AstraZeneca Pharma India Limited
―
Eris Lifesciences Ltd
―
PFIZER LIMITED
―
Piramal Pharma Limited
―